Interaction Checker

Interacciones de Trastuzumab

Trastuzumab (Herceptin, Ogivri, Kanjinti) tiene 75 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 4; moderadas: 48; leves: 23; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (4)

  • CiclofosfamidainmunosupresorGrave

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DoxorubicinaGrave

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Itraconazolantifúngico azólicoGrave

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

  • PaclitaxelGrave

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (etiqueta de Trastuzumab, Advertencias y precauciones)

Interacciones moderadas (48)

  • AclidinioanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • AdrenalinasimpaticomiméticoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • AminofilinametilxantinaModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Arformoterolagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Articaína y adrenalinaanestésico localModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Bupivacaína y adrenalinaanestésico localModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • CarboplatinoModerada

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DifenhidraminaantihistamínicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DocetaxelModerada

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Formoterolagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • IpratropioanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Ipratropio y salbutamolanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Levosalbutamolagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Lidocaína y adrenalinaanestésico localModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Prilocaína y adrenalinaanestésico localModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Salbutamolagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Salmeterolagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • TeofilinametilxantinaModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Terbutalinaagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • TiotropioanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • UmeclidinioanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Umeclidinio y vilanterolanticolinérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Vibegrónagonista beta-adrenérgicoModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

Menciones leves (23)

  • AzelastinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Bromfeniramina, pseudoefedrina y dextrometorfanoantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • CarbinoxaminaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • CetirizinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • CiproheptadinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • ClemastinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • ClorfenaminaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DesloratadinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DexclorfeniraminaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DimenhidrinatoantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • DoxilaminaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Doxilamina y piridoxinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • FexofenadinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Hidrocodona y clorfenaminaopioideLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • HidroxizinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • LevocetirizinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • LoratadinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • MeclozinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • OlopatadinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Palbociclibinhibidor de CYP3A4Leve

    Grade ≥3 neutropenia was reported in 61% of patients receiving IBRANCE in combination with trastuzumab, with or without pertuzumab, and endocrine therapy. (etiqueta de Palbociclib, Advertencias y precauciones)

  • PrometazinaantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Prometazina y codeínaopioideLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoLeve

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (etiqueta de Trastuzumab, Advertencias y precauciones)

Compruebe Trastuzumab frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.